- Protagonist Therapeutics (PTGX, Financial) will present VERIFY Phase 3 trial results at the ASCO Annual Meeting's Plenary Session on June 1, 2025.
- The VERIFY study assesses the effectiveness of Rusfertide in treating Polycythemia Vera (PV).
- Dr. Andrew T. Kuykendall of Moffitt Cancer Center will deliver the presentation.
Protagonist Therapeutics (PTGX) has announced that findings from its VERIFY Phase 3 study of Rusfertide, aimed at treating Polycythemia Vera (PV), will be showcased at the American Society of Clinical Oncology (ASCO) Annual Meeting. Selected for a plenary session, the presentation underscores the study's significance in the medical community. The event is scheduled from May 30 to June 3, 2025, and the presentation will occur on June 1, at 2:09 PM CDT, at McCormick Place, Hall B1.
The VERIFY study is designed as a double-blind, placebo-controlled Phase 3 trial, primarily evaluating Rusfertide's effectiveness as a treatment for PV. This inclusion in the plenary session notably highlights the potential impact and importance of the clinical results.
Dr. Andrew T. Kuykendall from Moffitt Cancer Center will present the results, representing a key moment for Protagonist Therapeutics in their ongoing development of innovative treatments. This development follows the company’s strategic partnership with Takeda Pharmaceuticals to co-develop and co-commercialize Rusfertide under a worldwide collaboration and license agreement.
This presentation at ASCO provides a major platform to share these crucial findings with the broader oncology and hematology communities, potentially influencing future treatment options for Polycythemia Vera.
